leadf
logo-loader
viewVolitionRx

VolitionRX progressing towards launch of first commercial products using Nu.Q platform

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds tells Proactive the firm rounded out the second quarter with $21.3 million in cash and equivalents compared to $12 million in the same quarter a year ago. The company's now tested two independent cohorts of COVID-19 positive patients with quantitative nucleosome immunoassays and found that nucleosomes were “highly elevated” in plasma of severe COVID-19 patients relative to healthy control subjects. Reynolds says the data implies that Nu.Q could have strong prognostic potential.

Quick facts: VolitionRx

Price: 4.01 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $193.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

VolitionRx Limited ends its 3Q with $21M in the bank, looks forward to...

VolitionRx Limited (NYSE AMERICAN:VNRX) CEO Cameron Reynolds tells Proactive the group finished its third quarter with around $21M in the bank compared with $17M at the end of 2019. Reynolds also discussed upcoming milestones including the preparing to launch its new product, Nu.Q™ Vet Cancer...

on 11/13/2020

2 min read